 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...5859606162636465666768...100101» |
- | letrozole / Generic mfg.
Journal: Effects of Electroacupuncture on Ovarian Expression of the Androgen Receptor and Connexin 43 in Rats with Letrozole-Induced Polycystic Ovaries. (Pubmed Central) - Aug 1, 2020
Furthermore, EA counteracted the letrozole-induced upregulation of AR and Cx43. These results suggested that acupuncture can break the vicious cycle initiated by excessive androgen secretion and may be an effective treatment method for improving the reproductive and endocrine dysfunction caused by PCOS.
- |||| letrozole / Generic mfg.
Clinical: Still using it quite a lot! #Letrozole We @MDAndersonNews did a prospective trial many years ago in heavily pretreated recurrent #ovariancancer and response rates above 20%...so as good as any chemo @IJGConline @IJGCfellows @IGCSociety @ESGO_society @GynMe4 (Twitter) - Jul 31, 2020
- || letrozole / Generic mfg.
Retrospective data, Review, Journal: Gonadotropins versus oral ovarian stimulation agents for unexplained infertility: a systematic review and meta-analysis. (Pubmed Central) - Jul 29, 2020
For every birth gained with the use of gonadotropins, a similar increased risk of multiple gestation occurs. The randomized data do not support the use of gonadotropin for OS-IUI in women with unexplained infertility.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New P2 trial: MUKDEN 01: Pyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial (clinicaltrials.gov) - Jul 26, 2020
P2, N=89, Not yet recruiting, Sponsor: Shengjing Hospital
- | fovinaciclib (FCN-437) / Fosun Pharma
New P1/2 trial: Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c (clinicaltrials.gov) - Jul 26, 2020
P1/2, N=78, Recruiting, Sponsor: Ahon Pharmaceutical Co., Ltd.
- || letrozole / Generic mfg.
Clinical, Journal: Does empiric superovulation improve fecundity in healthy women undergoing therapeutic donor insemination without a male partner? (Pubmed Central) - Jul 25, 2020
Patients undergoing unmedicated TDI cycles had higher fecundity and no incidence of twin gestations. Older women, those with low AMH, and those who fail to conceive after three unmedicated cycles may benefit from medication.
- | letrozole / Generic mfg.
Journal: Evidence-based treatments for couples with unexplained infertility: a guideline. (Pubmed Central) - Jul 24, 2020
The treatment of unexplained infertility is by necessity empiric. For most couples, the best initial therapy is a course (typically 3 or 4 cycles) of ovarian stimulation with oral medications and intrauterine insemination (OS-IUI) followed by in vitro fertilization for those unsuccessful with OS-IUI treatments.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, letrozole / Generic mfg., Faslodex (fulvestrant) / AstraZeneca
Clinical, Journal: Two Cases of Stage Ⅳ Occult Breast Cancer (Pubmed Central) - Jul 24, 2020
However, after 6 months, she discontinued the treatment. Our results suggested that effective control could be achieved through systemic therapy and local therapy was not necessary for Stage Ⅳ occult breast cancer.
- [VIRTUAL] TransFAL: Establishment of clinical trial-matched luminal breast cancer patient-derived xenografts (PDX) for translational studies (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1497;
P2
Background PARSIFAL was a randomized phase II trial aimed at evaluating the efficacy of palbociclib (P) plus either fulvestrant (F) or letrozole (L) in Estrogen Receptor[+]/Human Epidermal Growth Factor Receptor 2[-] metastatic breast cancer...The P+L-resistant tumors were also resistant to P+F in vivo but sensitive to the PI3K-α inhibitor alpelisib plus F ex vivo...Funding: Pfizer. Clinical trial identification: NCT02491983.
- |||| Tecentriq (atezolizumab) / Roche
New P1/2 trial, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, MSi-H Companion diagnostic, PARP Companion diagnostic, PD(L)-1 companion diagnostic: AFT-50 EndoMAP: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) - Jul 23, 2020
P1/2, N=60, Not yet recruiting, Sponsor: Alliance Foundation Trials, LLC.
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Combination therapy, Metastases: PALINA: Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer (clinicaltrials.gov) - Jul 23, 2020
P2/3, N=35, Active, not recruiting, Sponsor: Georgetown University
Clinical trial identification: NCT02491983. Trial completion date: Jun 2020 --> Dec 2020
- | Ibrance (palbociclib) / Pfizer, everolimus / Generic mfg.
Retrospective data, Journal: Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer. (Pubmed Central) - Jul 22, 2020
Palbociclib is effective for HR+/HER2- MBC in real-world practice. Hormone therapy alone or in combination with targeted agents remains an effective option after palbociclib progression.
- | Journal: Investigation of Anti-Cancer Drugs Suspected as Causative Agents of Allergy by Drug-Induced Lymphocyte Stimulation Test and Subsequent Re-Administration (Pubmed Central) - Jul 22, 2020
The other patient received lenalidomide in combination with dose-reduction and prednisolone(PSL), and the patient did not relapse...These results confirmed that re-administration was possible depending on the type of side effects even in DLST positive cases; however, it was necessary to take various precautions. Moreover, DLST results were an index for finding the cause, and it is important to consider other diagnostic methods carefully during re-administration.
- everolimus / Generic mfg.
[VIRTUAL] Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_657;
Legal entity responsible for the study: Fondazione IRCCS Istituto Nazionale dei Tumori. Funding: Has not received any funding.
- Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg., fulvestrant / Generic mfg.
[VIRTUAL] PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC) (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_654;
P1
Funding: F. Hoffmann-La Roche Ltd. Clinical trial identification: NCT03006172.
- letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
[VIRTUAL] Ribociclib (RIB) + letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_651;
P3
Funding: Novartis Pharmaceuticals Corporation. Clinical trial identification: NCT02941926.
- [VIRTUAL] Comparative effectiveness of ribociclib plus fulvestrant (RIB+FUL) versus palbociclib plus letrozole (PAL+LET) as first-line (1L) treatment (Tx) of HR+/HER2− advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC) (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_648;
Legal entity responsible for the study: Novartis Pharmaceuticals Corporation. Funding: Novartis Pharmaceuticals Corporation.
- letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
[VIRTUAL] Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib + letrozole HR+ HER2- advanced breast cancer trial (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_635;
P3
Funding: Novartis Pharmaceuticals Canada. Clinical trial identification: NCT02941926.
- letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica
[VIRTUAL] Impact of chemotherapy and hormonotherapy on acute skin toxicity of hypofractionated breast cancer radiotherapy (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_541;
Legal entity responsible for the study: Lotfi Kochbati. Funding: Has not received any funding.
- letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, tamoxifen / Generic mfg.
[VIRTUAL] Lipid changes during endocrine therapy in breast cancer patients: The results of a 5-year real-world retrospective analysis (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_527;
Results For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifene (TAM) group compared with baseline (p<0.05), and the decline remained for the following 4 years...For postmenopausal BC patients, there was no statistical difference in the lipid profiles (TG, TC, LDL and HDL) in letrozole (LET), anastrozole (ANA) and exemestane (EXE) group compared with the control group, respectively...Legal entity responsible for the study: West China School of Medicine/West China Hospital, Sichuan University. Funding: Has not received any funding.
- [VIRTUAL] BioItaLEE: Molecular features of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) PIK3CA-mutated advanced breast cancer (ABC) on first-line treatment with ribociclib + letrozole and on second-line treatment with alpelisib + fulvestrant (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_495;
P3
Funding: Novartis Farma SpA, Origgio, Italy. Clinical trial identification: NCT03439046.
- || Ibrance (palbociclib) / Pfizer
Clinical, Clinical data, Journal, HEOR, Real-World Evidence: Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study. (Pubmed Central) - Jul 21, 2020
Clinical trial identification: NCT03439046. Results from this first real-world evaluation of clinical outcomes in Argentina suggest that palbociclib plus letrozole or fulvestrant delivers favorable effectiveness, as measured by progression-free and overall survival rates.
- ||| Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg.
Clinical, P3 data, Journal: Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study. (Pubmed Central) - Jul 21, 2020
Consistent with the overall study population, the addition of palbociclib to letrozole significantly improved PFS in Asians. Hematologic toxicities were more frequent in Asians versus non-Asians but manageable with early dose modifications while maintaining QOL.
- | NN1213 / Novo Nordisk
Enrollment closed, Trial completion date: BARONET: Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers (clinicaltrials.gov) - Jul 21, 2020
P=N/A, N=40, Active, not recruiting, Sponsor: NHS Tayside
Hematologic toxicities were more frequent in Asians versus non-Asians but manageable with early dose modifications while maintaining QOL. Recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> May 2022
- |||| taselisib (GDC-0032) / Roche
Enrollment open, Combination therapy, Metastases: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (clinicaltrials.gov) - Jul 20, 2020
P1/2, N=685, Recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> May 2022 Active, not recruiting --> Recruiting
- | Soltamox (tamoxifen citrate) / Jazz
Enrollment closed, Trial completion date, Trial primary completion date: PRO30178: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer (clinicaltrials.gov) - Jul 20, 2020
P2, N=42, Active, not recruiting, Sponsor: Medical College of Wisconsin
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Jul 2022 | Trial primary completion date: Jul 2020 --> Jul 2021
- |||||||||| amcenestrant (SAR439859) / Sanofi
New P3 trial, Metastases: AMEERA-5: Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (clinicaltrials.gov) - Jul 19, 2020
P3, N=708, Not yet recruiting, Sponsor: Sanofi
- || letrozole / Generic mfg.
Hi, Are you Novartis who first manufactured Femara/ Letrazole? (Twitter) - Jul 19, 2020
- || letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Clinical, Journal: Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. (Pubmed Central) - Jul 16, 2020
In the US subset of MONALEESA-2, ribociclib with letrozole showed superior efficacy versus letrozole alone. These findings are consistent with the global population and support first-line use of ribociclib with letrozole in patients with HR/HER2 ABC.
- || xentuzumab (BI-836845) / Boehringer Ingelheim
Trial completion date, Trial primary completion date, Combination therapy, Metastases: This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer (clinicaltrials.gov) - Jul 16, 2020
P1, N=148, Recruiting, Sponsor: Boehringer Ingelheim
These findings are consistent with the global population and support first-line use of ribociclib with letrozole in patients with HR/HER2 ABC. Trial completion date: Jun 2022 --> Jan 2023 | Trial primary completion date: Jan 2022 --> Aug 2022
- | Flagyl (metronidazole) / SLA, letrozole / Generic mfg.
Journal: Structural study of letrozole and metronidazole and formation of self-assembly with graphene and fullerene with the enhancement of physical, chemical and biological activities. (Pubmed Central) - Jul 15, 2020
Molecular docking studies indicate that the pure compounds and their self-assemblies with graphene have excellent biological activities. Communicated by Ramaswamy H. Sarma.
- | Phase classification, Enrollment change, Trial completion date, Trial primary completion date: EUROPA: ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ?70 Years Early Stage Breast Cancer (clinicaltrials.gov) - Jul 14, 2020
P3, N=926, Not yet recruiting, Sponsor: Azienda Ospedaliero-Universitaria Careggi
Communicated by Ramaswamy H. Sarma. Phase classification: P2/3 --> P3 | N=600 --> 926 | Trial completion date: Mar 2026 --> Dec 2025 | Trial primary completion date: Mar 2023 --> Dec 2025
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects (clinicaltrials.gov) - Jul 14, 2020
P1, N=60, Recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Phase classification: P2/3 --> P3 | N=600 --> 926 | Trial completion date: Mar 2026 --> Dec 2025 | Trial primary completion date: Mar 2023 --> Dec 2025 Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2020 --> Jun 2021
- | Verzenio (abemaciclib) / Eli Lilly
New P2 trial: Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer (clinicaltrials.gov) - Jul 13, 2020
P2, N=32, Not yet recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- || Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg.
Biomarker, Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer. (Pubmed Central) - Jul 11, 2020
P3
These data underscore the importance of CDK4/6 signaling in HR+/HER2‒ breast cancer and suggest that the interplay between steroid hormone and peptide growth factor signaling could drive dependence on CDK4/6 signaling. (Pfizer; NCT01740427).
- ||| BPI-1178 / Beta Pharma
Enrollment open, Trial initiation date, Combination therapy, Metastases: A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer (clinicaltrials.gov) - Jul 8, 2020
P1/2, N=100, Recruiting, Sponsor: Beta Pharma (Suzhou) Co., Ltd.
(Pfizer; NCT01740427). Not yet recruiting --> Recruiting | Initiation date: Mar 2020 --> Jun 2020
- || letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, exemestane / Generic mfg.
Clinical, Journal, Real-World Evidence: Fractures due to Aromatase Inhibitor Therapy for Breast Cancer: A Real-World Analysis of FAERS Data in the Past 15 Years. (Pubmed Central) - Jul 8, 2020
Anastrozole should be prescribed with more medical care. Analysis of FAERS data identified fracture risk tendencies with AI regimens, which supported continuous monitoring, risk evaluations, and further comparative studies.
- || Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jul 8, 2020
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Analysis of FAERS data identified fracture risk tendencies with AI regimens, which supported continuous monitoring, risk evaluations, and further comparative studies. Trial completion date: May 2023 --> Jan 2023 | Trial primary completion date: May 2023 --> Jan 2023
- | letrozole / Generic mfg.
Enrollment open: Novel Therapy for Poor Responders Management (clinicaltrials.gov) - Jul 7, 2020
P=N/A, N=100, Recruiting, Sponsor: Al Baraka Fertility Hospital
Trial completion date: May 2023 --> Jan 2023 | Trial primary completion date: May 2023 --> Jan 2023 Not yet recruiting --> Recruiting
- || Piqray (alpelisib) / Novartis, letrozole / Generic mfg.
Clinical, P2 data, Journal: A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). (Pubmed Central) - Jul 7, 2020
Not yet recruiting --> Recruiting In contrast to initial results in advanced/metastatic disease, addition of alpelisib to 24-week neoadjuvant letrozole treatment did not improve response in patients with HR+ early breast cancer.
- |||||| Ibrance (palbociclib) / Pfizer
New trial, HEOR, Real-world evidence, Real-world, Metastases: RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S. (clinicaltrials.gov) - Jul 7, 2020
P, N=1, Completed, Sponsor: Pfizer
- | Retrospective data, Journal: CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. (Pubmed Central) - Jul 7, 2020
In contrast to initial results in advanced/metastatic disease, addition of alpelisib to 24-week neoadjuvant letrozole treatment did not improve response in patients with HR+ early breast cancer. Since the addition of CDKI to endocrine therapy seemed to benefit all clinicopathological subgroups of interest in this pooled analysis, further research is needed to identify patient subgroups for whom endocrine therapy alone might be appropriate for first-line or second-line treatment of hormone receptor-positive, HER2-negative metastatic breast cancer.
- ||| letrozole / Generic mfg.
Clinical, P3 data, Clinical Trial,Phase III, Journal, Real-World Evidence: Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer. (Pubmed Central) - Jul 7, 2020
P3
The present study compared clinical outcomes in women with metastatic breast cancer who received letrozole as first-line monotherapy in oncology practices across the United States versus patients in the letrozole-alone cohort of the PALOMA-2 phase 3 trial...These data increase confidence in the use of real-world assessments of progression and response as efficacy endpoints. Trial registration NCT01740427; Funding: Pfizer.
- | letrozole / Generic mfg.
Phase classification, Trial completion date: RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF (clinicaltrials.gov) - Jul 7, 2020
P4, N=41, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Trial registration NCT01740427; Funding: Pfizer. Phase classification: P=N/A --> P4 | Trial completion date: Dec 2019 --> May 2021
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: PREDIX LumB: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (clinicaltrials.gov) - Jul 7, 2020
P2, N=180, Recruiting, Sponsor: Thomas Hatschek
Phase classification: P=N/A --> P4 | Trial completion date: Dec 2019 --> May 2021 Trial completion date: Jun 2024 --> Jun 2031 | Trial primary completion date: Jun 2018 --> Dec 2021
- Ibrance (palbociclib) / Pfizer
[VIRTUAL] A Tale of Unexplained Pneumotoxicity: The Dangers of Palbociclib (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_3978;
An exhaustive laboratory workup was done in order to exclude other causes that may result in diffuse lung injury, including infection, environmental exposure, and malignancy. This should not deter physicians from using palbociclib as a chemotherapeutic agent in patient with advanced stage breast cancer, as the PALOMA-2 trial has shown that combining palbociclib with letrozole can lead to a median progression free survival of thirteen months in patients who are ER-positive and HER2-negative.
- | letrozole / Generic mfg., methotrexate / Generic mfg.
Journal: Aromatase inhibitor letrozole: a novel treatment for ectopic pregnancy. (Pubmed Central) - Jul 6, 2020
To our knowledge, this is the first report in the literature on the success of letrozole for the medical treatment of ectopic pregnancy. The promisingly high resolution rate and better safety profile that letrozole has compared with a chemotherapeutic agent such as methotrexate should encourage further studies.
- || letrozole / Generic mfg., taselisib (GDC-0032) / Roche
Clinical, P2 data, Journal: Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. (Pubmed Central) - Jul 2, 2020
P2
The promisingly high resolution rate and better safety profile that letrozole has compared with a chemotherapeutic agent such as methotrexate should encourage further studies. The increase in the proportion of patients who achieved an objective response from the addition of taselisib to endocrine therapy in a neoadjuvant setting is consistent with the clinical benefit observed in hormone receptor-positive, HER2-negative, metastatic breast cancer.
- || letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, exemestane / Generic mfg.
Clinical, Journal: A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors (Pubmed Central) - Jul 1, 2020
BMD was declining steadily in patients treated with AIs, especially in the first year. Lumbar spine is the most common osteoporosis site, early prevention and health education should be strengthened.
- | letrozole / Generic mfg., Arimidex (anastrozole) / AstraZeneca, Remedica, exemestane / Generic mfg.
Review, Journal: Polyphenolic natural products and natural product-inspired steroidal mimics as aromatase inhibitors. (Pubmed Central) - Jun 29, 2020
Pursuit of this strategy over the last few decades has been largely successful although complications and challenges remain. This review highlights the aromatase activity of natural stilbenes, chalcones, and flavanones and synthetically inspired versions thereof and draws attention to new and under-investigated areas within each class worthy of pursuit.